Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence
This article was originally published in PharmAsia News
Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.
You may also be interested in...
Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.
Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.
Rubella Outbreak Sign Of Japan’s History Of Vaccination Gap; Takeda, Other Domestic Manufacturers Ramp Up Output
Domestic vaccine manufacturers such as Takeda are ramping up production to meet new demand, and MHLW is drafting policies to fill Japan’s rubella vaccination gap.